Evercore ISI Downgrades Ultragenyx Pharma (RARE) to In Line

September 3, 2026 2:36 AM

Evercore ISI analyst Gavin Clark-Gartner downgraded Ultragenyx Pharma (NASDAQ: RARE) from Outperform to In Line with a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found